A Study of a New Way to Treat Children and Young Adults With a Brain Tumor Called NGGCT

This phase II trial studies the best approach to combine chemotherapy and radiation therapy (RT) based on the patient's response to induction chemotherapy in patients with non-germinomatous germ cell tumors (NGGCT) that have not spread to other parts of the brain or body (localized). This study has 2 goals: 1) optimizing radiation for patients who respond well to induction chemotherapy to diminish spinal cord relapses, 2) utilizing higher dose chemotherapy followed by conventional RT in patients who did not respond to induction chemotherapy. Chemotherapy drugs, such as carboplatin, etoposide,

Trial Details

NCT ID

NCT04684368

Phase

PHASE2

Sponsor

Children's Oncology Group

Status

RECRUITING

Cancer Type

Brain Cancer

Interventions

Biospecimen Collection
Carboplatin
Etoposide
Filgrastim
Ifosfamide
Magnetic Resonance Imaging

Locations (sample)

Birmingham, Alabama, United States|33.52066,-86.80249
Anchorage, Alaska, United States|61.21806,-149.90028
Mesa, Arizona, United States|33.42227,-111.82264
Tucson, Arizona, United States|32.22174,-110.92648
Little Rock, Arkansas, United States|34.74648,-92.28959

Key Eligibility Criteria

Patients must be \>= 3 years and \< 30 years at the time of study enrollment
Patients must be newly diagnosed with localized primary CNS NGGCT of the suprasellar and/or pineal region by pathology and/or serum or cerebrospina…
Patients with any of the following pathological elements are eligible: endodermal sinus (yolk sac), embryonal carcinoma, choriocarcinoma, malignant…
Patients must have a cranial MRI with and without gadolinium at diagnosis/prior to enrollment. If surgical resection is performed, patients must ha…

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Brain Cancer Trials on Trialify →